参考文献
［1］ Philip PA，Benedetti J，Corless CL，et al.PhaseⅢstudy comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma：Southwest Oncology Groupdirected intergroup trial S0205［J］.J Clin Oncol，2010，28：3605-3610.
［2］ Kindler HL，Niedzwiecki D，Hollis D，et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer：phaseⅢtrial of the Cancer and Leukemia Group B（CALGB 80303）［J］.J Clin Oncol，2010，28：3617-3622.
［3］ Moore MJ，Goldstein D，Hamm J，et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer：aphaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group［J］.J Clin Oncol，2007，25：1960-1966.
［4］ Conroy T，Françoise Desseigne，Ychou M，et al.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer［J］.New England Journal of Medicine，2011，364（19）：1817-1825.
［5］ Kulke MH，Tempero MA，Niedzwiecki D，et al.Randomized phaseⅡstudy of gemcitabine administered at a fixed dose rate or in combination with cisplatin，docetaxel，or irinotecan in patients with metastatic pancreatic cancer：CALGB 89904［J］.J Clin Oncol，2009，27：5506-5512.
［6］ Cunningham D，Chau I，Stocken DD，et al.PhaseⅢrandomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer［J］.J Clin Oncol，2009，27：5513-5518.
［7］ Louvet C.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer：results of a GERCOR and GISCAD phaseⅢtrial［J］.Journal of Clinical Oncology，2005，23（15）：3509-3516.
［8］ Oettle H，Richards D，Ramanathan RK，et al.A phaseⅢtrial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer［J］.Ann Oncol，2005，16：1639-1645.
［9］ Abou-Alfa GK，Letourneau R，Harker G，et al.Randomized phaseⅢstudy of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer［J］.J Clin Oncol，2006，24：4441-4447.(https://www.daowen.com)
［10］ Tempero M，Plunkett W，Ruiz Van Haperen V，et al.Randomized phaseⅡcomparison of doseintense gemcitabine：thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma［J］.J Clin Oncol，2003，21：3402-3408.
［11］ Alhaddad M，Eloubeidi MA.Interventional EUS for the diagnosis and treatment of locally advanced pancreatic cancer［J］.Jop，2010，11（1）：1-7.
［12］ Bhatnagar S，Joshi S，Rana SPS，et al.Bedside ultrasound-guided celiac plexus neurolysis in upper abdominal cancer patients：a randomized，prospective study for comparison of percutaneous bilateral paramedian vs.unilateral paramedian needle-insertion technique［J］.Pain Pract，2014，14（2）：E63-68.
［13］ Artifon EL，Frazão MSV，Wodak S，et al.Endoscopic ultrasound-guided choledochoduodenostomy and duodenal stenting in patients with unresectable periampullary cancer：one-step procedure by using linear echoendoscope［J］.Scand J Gastroenterol，2013，48（3）：374-379.
［14］ Mella JM，Guidi M，María JD，et al.Endoscopic ultrasound-guided choledocho-duodenostomy in advanced pancreatic cancer with duodenal obstruction［J］.Medicina（B Aires），2015，75（5）：311-314.
［15］ Varadarajulu S，Bang JY.Role of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the clinical assessment of pancreatic neoplasms［J］.Surg Oncol Clin N Am，2016，25（2）：255-272.
［16］ Lee SH，et al.Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low-and intermediaterisk prostate cancer［J］.Asia Pac J Clin Oncol，2016，12（4）：388-395.
［17］ Qing SW，Ju XP，Cao YS，et al.Dose escalation of Stereotactic Body Radiotherapy（SBRT）for locally advanced unresectable pancreatic cancer patients with CyberKnife：protocol of a phaseⅠstudy［J］.Radiat Oncol，2017，12（1）：6.
［18］ 李茂全.晚期胰腺癌介入治疗临床操作指南（试行）［J］.临床放射学杂志，2016，33（11）：1626-1632.